Half-Year Financials, January 1 – June 30 2021
Faron Pharmaceuticals Oy (“Faron”) Faron Reports Half-Year Financials, January 1 – June 30, 2021 Significant progress made in H1 2021 including acceleration of most advanced pipeline assets - Bexmarilimab and Traumakine[Ò] August 26, 2021 at 7:00 am BST / 9:00 am EEST January – June 2021 in short/ Summary of January – June 2021 · Bexmarilimab shows compelling antitumor activity in multiple advanced solid tumor types as a monotherapy with strongest disease control rate, DCR (30.0% - 40.0%), observed in cutaneous melanoma, gastric cancer, cholangiocarcinoma and